Expected Moves

Expected progress update on Ovation's strategic partnership with Skinvisible regarding their patent-pending transdermal cannabinoid developments for the obesity market.

Q3 2026 financial results, which will test whether the expansion of the 'Mood' brand in Pennsylvania is generating meaningful wholesale royalties to offset cash burn.

Potential regulatory signals from the current administration regarding federal cannabis rescheduling or safe banking, which directly impacts Ovation's licensee base.

Full year 2026 earnings report and comprehensive annual audit, serving as the ultimate test of the company's going concern status.

Anticipated requirement for a capital raise or the conversion of existing debt into equity to maintain basic corporate solvency.